# Vedolizumab Plus Post-transplant Cyclophosphamide and Short Course Tacrolimus for the Prevention of Graft Versus Host Disease in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation After Reduced Intensity Conditioning

> **NCT06815003** · PHASE2 · RECRUITING · sponsor: **City of Hope Medical Center** · enrollment: 35 (estimated)

## Conditions studied

- Acute Lymphoblastic Leukemia
- Acute Myeloid Leukemia
- Chronic Myelomonocytic Leukemia
- Graft Versus Host Disease
- Myelodysplastic Syndrome
- Myeloproliferative Neoplasm

## Interventions

- **PROCEDURE:** Allogeneic Hematopoietic Stem Cell Transplantation
- **PROCEDURE:** Biospecimen Collection
- **PROCEDURE:** Bone Marrow Biopsy
- **PROCEDURE:** Computed Tomography
- **DRUG:** Cyclophosphamide
- **PROCEDURE:** Echocardiography
- **DRUG:** Fludarabine
- **DRUG:** Melphalan
- **PROCEDURE:** Multigated Acquisition Scan
- **OTHER:** Questionnaire Administration
- **DRUG:** Tacrolimus
- **BIOLOGICAL:** Vedolizumab

## Key facts

- **NCT ID:** NCT06815003
- **Lead sponsor:** City of Hope Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-04-18
- **Primary completion:** 2028-10-15
- **Final completion:** 2028-10-15
- **Target enrollment:** 35 (ESTIMATED)
- **Last updated:** 2025-06-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06815003

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06815003, "Vedolizumab Plus Post-transplant Cyclophosphamide and Short Course Tacrolimus for the Prevention of Graft Versus Host Disease in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation After Reduced Intensity Conditioning". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT06815003. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*